CD274 and hepatocellular carcinoma: The current FDA-approved first-line therapy for advanced HCC involving atezolizumab (an anti-PD-L1 antibody) + bevacizumab (an anti-VEGF antibody) regimen does not require the assessment of PD-L1 expression for its use.